In a report released today, Andrew Galler from Morgan Stanley maintained a Buy rating on Ionis Pharmaceuticals (IONS - Research Report), with a price target of $56.00. The company's shares opened today at $44.48.According to TipRanks, Galler is a 3-star analyst with an average return of 3.5% and a 60.00% success rate. Galler covers the Healthcare sector, focusing on stocks such as Immunocore Holdings, Alnylam Pharma, and Amicus.In addition to Morgan Stanley, Ionis Pharmaceuticals also received a Buy from BMO Capital's Gary Nachman in a report issued today. However, on the same day, Barclays maintained a Hold rating on Ionis Pharmaceuticals (NASDAQ: IONS).
https://www.tipranks.com/news/blurbs/ionis-pharmaceuticals-ions-receives-a-buy-from-morgan-stanley?utm_source=advfn.com&utm_medium=referral